It was just 6 months ago that vaccines specialist CSL closed on its $275 million buyout of Novartis' influenza vaccines operations, getting three additional plants in the process. But the company says more capacity is needed and expansion is already underway in the U.K.
Australia's CSL has been expanding around the world and now has taken its U.S.-based blood plasma business, CSL Behring, into Russia. It is following other pharma companies that are looking for growth there.
The U.S. has its first publicly available adjuvanted seasonal flu vaccine in Fluad, formerly a Novartis shot that is now owned by CSL's Seqirus unit.
Australia's CSL, which completed its acquisition of Novartis' flu vaccines business this year, has launched a AU$1 million share buyback.
The U.S. may be getting its first adjuvanted flu vaccine. On Tuesday, an FDA panel recommended accelerated approval of Novartis' Fluad--now owned by CSL's flu vaccine subsidiary--in individuals 65 and older.
CSL is now the second largest flu vaccine manufacturer in the world, thanks to its acquisition of Novartis' flu vaccine business. The company reported a AU$1.9 billion ($1.4 billion) full-year profit, a 6% increase over the previous year.
Australian vaccines maker CSL has plenty of wherewithal to make some deals, CEO Paul Perreault says, but he's wary of the prices paid by other drugmakers. Big Pharma's penchant for biotech deals has created "a bit of a bubble," in Perreault's view.
With the closing announced on Sunday of its $275 million purchase of Novartis' flu vaccine business, Australia's CSL is slated to become the world's second-largest flu vaccine supplier. It said on Friday that it secured the necessary approvals for the acquisition and worked through Sunday to finalize the deal.
Australia's CSL unveiled Phase III trial results for hemophilia B candidate rIX-FP that met the primary endpoint and separately noted it bought exclusive rights to commercialize flu treatment Rapivab from BioCryst Pharmaceuticals last week. The note highlighted the growing reach of the biopharma in a core blood products business and in vaccines following its purchase of a Novartis unit last year.
Australia's CSL will launch its new global flu vaccine business in early 2016, after it completes its $275 million acquisition of Novartis' flu vaccine unit.